Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Life After Treatment: Navigating Survivorship and Long-Term Health

At a Glance

After completing Non-Hodgkin Lymphoma treatment, survivorship focuses on monitoring for relapse through regular physical exams and blood work rather than routine scans. Patients should also monitor for long-term late effects like heart issues, persistent fatigue, and weakened immunity.

Completing treatment for Non-Hodgkin Lymphoma (NHL) is a major milestone, but it often marks the beginning of a new emotional and physical chapter called survivorship. This phase focuses on monitoring for the return of the cancer (relapse) and managing any late effects—side effects that may appear months or even years after treatment ends [1][2].

Long-Term Monitoring and Surveillance

Once you are in clinical remission, your care team will transition you to a surveillance schedule. Interestingly, for many patients, intensive imaging like PET or CT scans is actually not recommended on a routine basis if you have no symptoms [3][4]. Research shows that routine scans often have a low chance of finding a relapse early and can lead to unnecessary anxiety or “false positives” [5].

Instead, monitoring typically focuses on:

  • Physical Exams: Checking for new lumps or changes in your lymph nodes [1].
  • Blood Work: Regular tests to check your blood counts and markers like LDH [2].
  • Symptom Awareness: You are often the best “monitor” of your own health. Report any new fevers, night sweats, or unexplained pain immediately [6].

Typical Surveillance Schedule (First 5 Years)

While schedules vary by subtype (aggressive vs. indolent), a general framework includes [1][7]:

  • Years 1–2: Visits every 3 to 6 months.
  • Years 3–5: Visits every 6 to 12 months.
  • After 5 Years: Annual visits, often transitioning back to your primary care physician with a detailed “Survivorship Care Plan.”

Managing “Scanxiety”

The dread that builds before a follow-up scan is so common it has its own name: scanxiety [8]. It often peaks during the “waiting period” between the scan and the results [9].

  • Acknowledge it: Recognize that this anxiety is a normal, physiological response to a stressful event [10].
  • Stay Present: Cognitive strategies that focus on the “here and now” rather than imagining future “what-ifs” can help ground you [11].
  • Communicate: Ask your team exactly how and when you will receive results to reduce the uncertainty [12].

Potential Late Effects

Treatments like R-CHOP and radiation are powerful, and they can impact healthy organs over time.

  • Heart Health (Cardiotoxicity): Drugs called anthracyclines (like the “H” in CHOP) and radiation to the chest can increase the risk of heart failure or coronary artery disease later in life [13][14]. Regular heart check-ups (echocardiograms) may be needed [15].
  • Prolonged Immune Suppression: Maintenance therapies or CD20-targeted drugs like Rituximab can cause long-term B-cell depletion. This may lead to frequent sinus or respiratory infections that require careful monitoring and sometimes preventative antibiotics [16].
  • Chronic Fatigue: About 30% of survivors experience persistent tiredness that lasts for years after treatment [17][18].
  • Secondary Cancers: Survivors have a slightly higher risk of developing a new, unrelated cancer (Secondary Malignant Neoplasm) [19]. This is why staying up to date on standard screenings like mammograms and colonoscopies is vital [20].
  • Reproductive Health: Some treatments can impact fertility or sexual function. Discussing these concerns with a specialist can help you find supportive care [16][21].

Lifestyle Factors

Focus on a balanced diet and regular, moderate exercise. Studies show that safe, consistent physical activity can help alleviate chronic fatigue and improve overall quality of life during survivorship. Always consult your doctor before starting a new exercise routine [17].

Common questions in this guide

Will I need routine PET or CT scans after my NHL treatment is finished?
For many patients in clinical remission who do not have symptoms, routine imaging scans are not recommended. Research shows routine scans have a low chance of finding a relapse early and can cause unnecessary anxiety, so monitoring relies mostly on physical exams and blood tests.
How often will I need follow-up appointments after NHL treatment?
Surveillance schedules vary, but typically involve visits every 3 to 6 months for the first two years. During years three through five, visits space out to every 6 to 12 months. After five years, most patients transition to annual check-ups.
What are the long-term effects of NHL treatment on my heart?
Treatments involving anthracyclines or chest radiation can increase your risk of developing heart failure or coronary artery disease later in life. Because of this, your care team may recommend regular heart check-ups, including echocardiograms.
Why am I getting frequent infections after finishing NHL treatment?
Maintenance therapies and targeted drugs like Rituximab can cause long-term depletion of certain immune cells. This prolonged immune suppression can increase your risk for sinus and respiratory infections, sometimes requiring preventative antibiotics.
What is scanxiety and how can I manage it?
Scanxiety is the common feeling of dread or worry leading up to follow-up scans or while waiting for results. You can manage it by acknowledging the anxiety, practicing mindfulness to stay in the present moment, and establishing a clear timeline for receiving results with your medical team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are the cumulative doses of anthracyclines (like doxorubicin) I received, and how does that affect my long-term heart health?
  2. 2.Based on my subtype and treatment, what is my specific surveillance schedule for the next five years?
  3. 3.Which secondary cancers am I at the highest risk for, and which screenings (like mammograms or colonoscopies) should I prioritize?
  4. 4.Can we schedule a 'results appointment' shortly after my scans to minimize the time I spend waiting and worrying?
  5. 5.Is there a survivorship clinic or a cardio-oncologist at this center you can refer me to?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

    Chihara D, Oki Y, Fanale MA, et al.

    Annals of hematology 2019; (98(5)):1169-1176 doi:10.1007/s00277-018-3571-7.

    PMID: 30617643
  2. 2

    Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

    Hester LL, Park SI, Wood WA, et al.

    Cancer 2019; (125(7)):1101-1112 doi:10.1002/cncr.31821.

    PMID: 30548238
  3. 3

    Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

    Kurtz DM, Green MR, Bratman SV, et al.

    Blood 2015; (125(24)):3679-87 doi:10.1182/blood-2015-03-635169.

    PMID: 25887775
  4. 4

    Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

    Roschewski M, Dunleavy K, Pittaluga S, et al.

    The Lancet. Oncology 2015; (16(5)):541-9.

    PMID: 25842160
  5. 5

    Interim FDG-PET/CT for Response Assessment of Lymphoma.

    Zeman MN, Akin EA, Merryman RW, Jacene HA

    Seminars in nuclear medicine 2023; (53(3)):371-388 doi:10.1053/j.semnuclmed.2022.10.004.

    PMID: 36376131
  6. 6

    [Clinicopathological characteristics and prognosis of non-Hodgkin lymphoma in oral and maxillofacial regions: An analysis of 369 cases].

    Su Q, Peng X, Zhou CX, Yu GY

    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 2023; (55(1)):13-21.

    PMID: 36718684
  7. 7

    Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.

    Abuamsha H, Kadri AN, Hernandez AV

    Hematological oncology 2019; (37(3)):261-269 doi:10.1002/hon.2607.

    PMID: 30916804
  8. 8

    Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".

    Bauml JM, Troxel A, Epperson CN, et al.

    Lung cancer (Amsterdam, Netherlands) 2016; (100()):110-113 doi:10.1016/j.lungcan.2016.08.002.

    PMID: 27597289
  9. 9

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  10. 10

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  11. 11

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  12. 12

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  13. 13

    Different manifestation of irradiation induced coronary artery disease detected with coronary computed tomography compared with matched non-irradiated controls.

    van Rosendael AR, Daniëls LA, Dimitriu-Leen AC, et al.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2017; (125(1)):55-61 doi:10.1016/j.radonc.2017.09.008.

    PMID: 28987749
  14. 14

    Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.

    Linschoten M, Kamphuis JAM, van Rhenen A, et al.

    The Lancet. Haematology 2020; (7(4)):e295-e308 doi:10.1016/S2352-3026(20)30031-4.

    PMID: 32135128
  15. 15

    Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.

    Barbosa MF, Fusco DR, Gaiolla RD, et al.

    BMC cardiovascular disorders 2021; (21(1)):170 doi:10.1186/s12872-021-01996-6.

    PMID: 33845778
  16. 16

    Erectile dysfunction in male lymphoma survivors in a Southeast Asian country.

    Gan GG, Ching Ng DL, Leong YC

    Singapore medical journal 2022; (63(7)):376-380 doi:10.11622/smedj.2021003.

    PMID: 33472336
  17. 17

    Persistent fatigue among long-term non-Hodgkin lymphoma survivors.

    LeBlanc MR, Zimmerman S, LeBlanc TW, et al.

    Leukemia & lymphoma 2022; (63(2)):344-352 doi:10.1080/10428194.2021.1984450.

    PMID: 34612771
  18. 18

    Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.

    Strongman H, Gadd S, Matthews A, et al.

    Lancet (London, England) 2019; (394(10203)):1041-1054 doi:10.1016/S0140-6736(19)31674-5.

    PMID: 31443926
  19. 19

    Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group.

    Moser O, Zimmermann M, Meyer U, et al.

    Haematologica 2021; (106(5)):1390-1400 doi:10.3324/haematol.2019.244780.

    PMID: 32299903
  20. 20

    Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.

    Boddicker NJ, Larson MC, Castellino A, et al.

    American journal of hematology 2021; (96(8)):979-988 doi:10.1002/ajh.26230.

    PMID: 33971040
  21. 21

    Sexual dysfunction is highly prevalent in male survivors of malignant lymphoma.

    Micas Pedersen S, Nielsen TH, Gang AO, et al.

    Sexual medicine 2023; (11(2)):qfad021 doi:10.1093/sexmed/qfad021.

    PMID: 37256215

This page explains survivorship and long-term monitoring for Non-Hodgkin Lymphoma for educational purposes only. Always consult your oncology team or primary care doctor for personalized medical advice and your specific follow-up care plan.

Get notified when new evidence is published on Non-Hodgkin lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.